ABT.L -

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Thomson Reuters StreetEventsyesterday

    Edited Transcript of ABT earnings conference call or presentation 17-Jul-19 1:00pm GMT

    Q2 2019 Abbott Laboratories Earnings Call

  • Abbott Laboratories (ABT) Q2 2019 Earnings Call Transcript
    Motley Fool2 days ago

    Abbott Laboratories (ABT) Q2 2019 Earnings Call Transcript

    ABT earnings call for the period ending June 30, 2019.

  • MarketWatch2 days ago

    Abbott stock rises after earnings beat, full-year guidance boost

    Shares of Abbott Laboratories gained 0.8% in premarket trade Wednesday after the medical-device maker reported second-quarter earnings that topped Wall Street expectations and raised full-year guidance, though the company missed expectations for revenue. Profit for the latest quarter rose to $1.465 billion, or 56 cents a share, from $733 million, or 41 cents a share, from the year-earlier quarter. Adjusted EPS was 82 cents, topping the FactSet consensus of 80 cents. Revenue rose 2.7% to $7.979 billion from $7.767 billion a year ago. Analysts polled by FactSet had expected $7.997 billion in sales. Sales of the company's nutrition unit rose 0.9% to $1.875 billion, while the diagnostics sales rose 1.7% to $1.905 billion. Sales of the established pharmaceuticals business fell 1.8% to $1.108 billion, while sales of the medical devices unit rose 6.4% to $3.075 billion, boosted by strong sales of the company's FreeStyle Libre glucose monitoring system and MitraClip. Abbott raised its full-year EPS to between $3.21 and $3.27 from between $3.15 and $3.25. "Our sales growth accelerated and is sustainable," Abbott's Chief Executive Miles D. White said in a statement. "We have great momentum and are raising our guidance above the strong outlook we previously set for the year." Shares of Abbott have gained 15% so far this year through Tuesday, while the S&P 500 has gained 19.8%.

  • ACCESSWIRE2 days ago

    Abbott Laboratories to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 17, 2019 / Abbott Laboratories (NYSE: ABT ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 17, 2019 at 9:00 AM Eastern ...

  • Morningstar6 days ago

    The Week Ahead: Earnings Season Heats Up

    We're watching earnings from several wide- and narrow-moat companies, plus retail sales and housing starts.

  • The 10 Biggest Healthcare Stocks
    Motley Fool9 days ago

    The 10 Biggest Healthcare Stocks

    How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

  • Moody's23 days ago

    Abbott Ireland Financing DAC -- Moody's announces completion of a periodic review of ratings of Abbott Laboratories

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Abbott Laboratories. Global Credit Research- 26 Jun 2019. New York, June 26, 2019-- Moody's Investors Service ...

  • CNBC2 months ago

    One sector is making a comeback amid market volatility

    Prepare for more churn around these levels, said  Mark Tepper , president of Strategic Wealth Partners. "We're really trying to target good companies that are big players in investible themes, and health care as a sector has struggled this year but it's been resilient over the past month. As the S&P 500 has tumbled 4% this month, the XLV health care sector ETF has held slightly positive.

  • 3 Dividend Aristocrats to Buy and Hold Forever
    Motley Fool2 months ago

    3 Dividend Aristocrats to Buy and Hold Forever

    Stable businesses that dole out a regular paycheck are like a warm blankie for your portfolio.

  • Moody's3 months ago

    Abbott Ireland Financing DAC -- Moody's upgrades Abbott Laboratories' senior unsecured rating to A3, stable outlook

    Moody's Investors Service ("Moody's") upgraded the senior unsecured ratings of Abbott Laboratories' ("Abbott") and its guaranteed subsidiary Abbott Ireland Financing DAC's to A3 from Baa1. Moody's also affirmed Abbott's commercial paper rating at Prime-2. The upgrade reflects Moody's expectations that Abbott will continue to operate with moderate financial leverage with debt/EBITDA sustained below 3.0 times.

  • GuruFocus.com3 months ago

    Weekly Top Insider Buys Highlight for the Week of April 26

    The largest Insider Buys this week were for Abbott Laboratories, Morgan Stanley, Crown Castle International Corp and Pinterest Inc.

  • FreeStyle Libre Is Multi-Billion Dollar Opportunity for Abbott
    Market Realist3 months ago

    FreeStyle Libre Is Multi-Billion Dollar Opportunity for Abbott

    ABT or BSX: Which Is a More Attractive Pick in April?(Continued from Prior Part)Diabetes Care revenues In the first quarter, Abbott Laboratories’ (ABT) Diabetes Care franchise reported worldwide sales of $566 million, a YoY rise of 34.4% on a

  • ABT and BSX: A Look at Segmental Performance in Fiscal 2019
    Market Realist3 months ago

    ABT and BSX: A Look at Segmental Performance in Fiscal 2019

    ABT or BSX: Which Is a More Attractive Pick in April?(Continued from Prior Part)Abbott Laboratories’ Segmental performanceIn its first-quarter earnings conference call, Abbott Laboratories (ABT) guided for mid-single-digit growth for its

  • What to Expect from ABT and BSX’s Margins
    Market Realist3 months ago

    What to Expect from ABT and BSX’s Margins

    ABT or BSX: Which Is a More Attractive Pick in April?(Continued from Prior Part)Margin guidance In its first quarter earnings conference call, Abbott Laboratories (ABT) guided for a fiscal 2019 adjusted gross margin ratio of 59.5% driven by

  • ABT and BSX: Comparing Revenue Performance for Fiscal 2019
    Market Realist3 months ago

    ABT and BSX: Comparing Revenue Performance for Fiscal 2019

    ABT or BSX: Which Is a More Attractive Pick in April?(Continued from Prior Part)Revenue guidance In its first-quarter earnings conference call, Abbott Laboratories (ABT) reiterated its YoY organic sales growth rate of 6.5%–7.5% for fiscal 2019.

  • How ABT and BSX Stack Up in the First Quarter of 2019
    Market Realist3 months ago

    How ABT and BSX Stack Up in the First Quarter of 2019

    ABT or BSX: Which Is a More Attractive Pick in April?(Continued from Prior Part)Abbott’s performance in the first quarter Abbott Laboratories (ABT) released its first-quarter earnings on April 17. The company reported revenues of $7.54 billion, a

  • What Are Analysts Recommending for ABT and BSX?
    Market Realist3 months ago

    What Are Analysts Recommending for ABT and BSX?

    ABT or BSX: Which Is a More Attractive Pick in April?Stock price movements On April 18, Abbott Laboratories (ABT) closed at $73.92, 1.43% higher than its previous closing price, 30.12% higher than its 52-week low of $56.81, and 8.45% below its

  • You can capture a dividend above 5% and still enjoy stock-market growth
    MarketWatch3 months ago

    You can capture a dividend above 5% and still enjoy stock-market growth

    Jeff Jonas of Gabelli talks about a closed-end fund that invests in the health-care and consumer staples sectors.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ABT earnings conference call or presentation 17-Apr-19 1:00pm GMT

    Q1 2019 Abbott Laboratories Earnings Call

  • A Diabetes Treatment Revolution Could Bolster These Medtech Firms
    Investor's Business Daily3 months ago

    A Diabetes Treatment Revolution Could Bolster These Medtech Firms

    Medical device companies like Abbott, Medtronic and Tandem Diabetes are jockeying for a piece of the diabetes treatment market, which could be worth north of $2 trillion by 2030.

  • Here's Why Abbott Labs Stock Is Slipping Despite Its Quarterly Beat
    Investor's Business Daily3 months ago

    Here's Why Abbott Labs Stock Is Slipping Despite Its Quarterly Beat

    Abbott Laboratories' earnings and sales topped first-quarter estimates, but the medical products giant retained its prior full-year outlook and Abbott stock slipped at the close Wednesday.

  • Abbott Labs Starts 2019 Off by Beating Expectations
    Motley Fool3 months ago

    Abbott Labs Starts 2019 Off by Beating Expectations

    The big healthcare company reported strong earnings growth in Q1.

  • Abbott Laboratories Jumps on 1st-Quarter Results
    GuruFocus.com3 months ago

    Abbott Laboratories Jumps on 1st-Quarter Results

    The US health care company beats expectations on non-GAAP earnings and sales